Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
French pharmaceutical company Sanofi on Friday announced the launch of human trials of its next COVID-19 vaccine, with its first still in the testing period after having fallen behind in development.
Sanofi and US firm Translate Bio are growing the vaccine based on messenger RNA technology.
The phase 1 and 2 trials aim to confirm that the vaccine is not dangerous and to provide initial information on its effectiveness.
Phase 3 could be carried out on many more patients to find out its effectiveness.
The first trials will include 415 people, with inital results anticipated in the third quarter.
Messenger RNA technology can be used in the Pfizer/BioNTech and Moderna vaccines, already authorised in the European Union, America and elsewhere.
It’s the second vaccine developed by Sanofi against the coronavirus.
An earlier candidate, developed with Britain’s GSK, is recombinant protein-based, but its development is a few months behind schedule and testing is only in stage 2, with hopes to launch it in late 2021.
